CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
This year’s annual scientific meeting was held in Austin, Texas (15-18 June 2023), with participants attending in-person and online.
Treating patients with migraine and major depressive disorder with fremanezumab is associated with significant reductions in Hamilton Depression Rating Scale-17 Items (HAMD-17) and Patient Health Questionnaire-9 (PHQ-9) scores over eight weeks, with effects maintained for 24 weeks.1 These are the key findings of the UNITE study (NCT04041284) – a Phase 4, 12-week double-blind, placebo controlled study …
Read more »CGRP mAb use is significantly associated with current antidepressant use for migraine (odds ratio [OR]=2.25; 95% confidence interval [CI]: 1.94–2.62), having a contraindication to triptans (OR=2.12; 95% CI: 1.87-2.41), current use of cardiovascular medication for migraine (OR=2.00; 95% CI: 1.71-2.34), and current use of 2+ recommended non-CGRP mAb preventive medications (OR=1.31; 95% CI: 1.05-1.65) The …
Read more »Real world cardiovascular and cerebrovascular event risks for patients with migraine are comparable with erenumab and other migraine preventive therapies, including other CGRP mAbs. This is the conclusion from an analysis of US prescription claims data for 53,877 new users of migraine prevention medications (erenumab, n=19,220; other mAbs, n=23,244; onabotulinumtoxinA, n=11,413). The relative risk (RR), …
Read more »A subgroup analysis of 1-year safety data for acute migraine treatment with zavegepant 10 mg nasal spray supports the drug’s safety and tolerability when used concomitantly with CGRP mAbs for preventive treatment.1 Of the 603 patients treated with zavegepant in the original Phase 2/3, 1-year open label study,2 39 (6.5%) reported current or concomitant use …
Read more »Marked and sustained reductions in monthly migraine days (MMDs) and improvements in migraine severity and burden for up to 18 months have been reported from the DELIVER study of eptinezumab in patients with migraine who had two to four documented preventive treatment failures (NCT04418765). In an analysis of 782/865 (90.4%) of patients who completed the 48 …
Read more »Combining remote electrical neuromodulation (REN) with gepants for the acute treatment of migraine may be more effective than REN alone. This conclusion is supported by results of a prospective real world study of REN to treat migraine attacks, with or without a gepant. At the onset of treatment, and two hours later, REN users were …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
